UBS analyst Kevin Caliendo upgraded LifeStance (LFST) to Buy from Neutral with an unchanged price target of $8.50. The firm we sees a fundamental disconnect between the company’s underlying performance and the stock’s valuation today. The recent stock weakness is related to investor de-risking and “some perhaps misunderstood headlines” coming out of the Q1 print, the analyst tells investors in a research note. UBS says there is “noise” surrounding LifeStance’s pause in federal enforcement of the mental health parity rule, which should have no impact to reimbursement rates or its rate improvement trajectory.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFST:
- Positive Outlook on LifeStance Health Group: Strong Financial Performance and Strategic Growth Initiatives
- LifeStance Health Group Appoints New Chief Technology Officer
- LifeStance appoints Vaughn Paunovich as CTO
- LifeStance Health Exceeds Q1 2025 Expectations
- Lifestance Health Group: Favorable Financial Performance and Strategic Shifts Present Buying Opportunity